Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P05452
UPID:
TETN_HUMAN
Alternative names:
C-type lectin domain family 3 member B; Plasminogen kringle 4-binding protein
Alternative UPACC:
P05452; Q6FGX6
Background:
Tetranectin, known as C-type lectin domain family 3 member B, plays a pivotal role in retinal function and exocytosis. It binds to plasminogen and kringle 4, indicating its involvement in blood clotting processes.
Therapeutic significance:
Linked to Macular dystrophy, retinal, 4, Tetranectin's dysfunction highlights its potential as a target for therapeutic intervention in retinal degenerative diseases.